AbbVie's board recommends that the company not purchase Shire.
Amgen is developing a biosimilar of AbbVie's Humira.
Investing in dividend stocks might appear easy, but not all dividends are really pulling their weight. After biopharmaceutical giants Amgen and AbbVie face off, find out which company is really the better dividend stock for investors.
Botox-maker Allergan has attracted activist investors in droves lately. Here's why.
The healthcare version of Where the Money Is.
With earnings tumbling over the patent cliff, can diabetes and oncology transform Eli Lilly into a Big Pharma turnaround story?
Celgene shares are up more than 1,200% over the past decade. But these three headwinds could be the brick wall that sends its stock lower.
Achillion stock is among the top gainers as its experimental hepatitis C combination therapy delivers "perfect" results.
A long-awaited mega-merger is announced, Exelixis reminds Wall Street that its pipeline is more than a single compound, and Amgen shows flashes of what's coming down its pipeline.
A new class of cholesterol drugs including Amgen's (AMGN) evolocumab could soon be competing for Aegerion's (AEGR) market share in HoFH patients.